Weekly Medical Cannabis & Science Literature Radar: September 13, 2026
A comprehensive weekly literature index analyzing 20 newly published medical cannabis, cannabinoid, and GLP-1 research studies, clinical trial protocols, and regulatory updates.
HHC Has Its Own Schedule I Code Now, and a Second Federal Deadline Lands in November
Patients keep asking one question, is HHC legal, and the federal answer now arrives through two separate instruments. The DEA gave hexahydrocannabinol its own Schedule I drug code on May 4, 2026, describing the listing as formalizing control that already…
A Cannabinoid Agonist Raised Insulin Sensitivity and a CB1 Blocker Lowered It: Inside an NIH Clamp Study
A National Institute on Aging crossover study used sequential glucose clamps in 21 healthy men to test whether the endocannabinoid system insulin sensitivity link holds up under direct measurement. The cannabinoid agonist nabilone significantly raised…
Short Trials Found Almost Nothing for MS Spasticity. Longer Trials Found More. The Numbers Need Care.
A nine-trial meta-analysis of 2,544 patients speaks to how long cannabis takes to work for MS spasticity, finding no statistically significant benefit in short-duration trials and much larger effects in longer ones. The pooled magnitudes are not usable,…
A Paris Laboratory Found That CBD Blocks HIV in Human Tissue. It Is Not a Prevention Strategy.
New laboratory work on CBD and HIV transmission comes from Institut Cochin in Paris, where cannabidiol inhibited HIV-1 infection of mucosal immune cells through the TRPV1 channel rather than through cannabinoid receptors. The effect held in donated human…
Running CBD and the Ketogenic Diet Together: What a 58-Patient Johns Hopkins Cohort Found
A multicenter Johns Hopkins cohort of 58 patients is the first published account of using CBD and ketogenic diet for epilepsy at the same time, and ketosis held in 87 percent of them. Seizure outcomes resembled what either therapy produces alone, with…
A Rare Class of Plant Molecule Turned Up in Cannabis Leaves, and Nobody Has Tested What It Does
Chemists at Stellenbosch University reported cannabis flavoalkaloids for the first time, sixteen compounds in four classes found mainly in the leaves of one of three cultivars analyzed. Every identification is tentative, the alkaloid portions could not…
A Phase 3 Trial Put a Cannabis Extract Head to Head With Opioids. The Primary Endpoint Was Constipation.
A randomized phase 3 trial of cannabis extract vs opioids in 384 adults with chronic low back pain made constipation its primary endpoint, and the extract group was roughly fourfold less likely to develop it. Pain relief favored the extract by 0.34…
Two Major 2026 Reviews Went Looking for Cannabis Trials in Depression. One Found None at All.
Two systematic reviews published in 2026 searched forty-five years of psychiatric trials, and the column for cannabis for depression came back effectively empty. One review found no qualifying randomized trial at all, and the other found a pooled effect…
24 Million Americans Microdose Cannabis: What the New National Data Means for Patients and Clinicians
New national survey data show that cannabis microdosing is now the most common form of microdosing in the United States, reported by 9.4 percent of adults. Unlike psilocybin, LSD, or MDMA, cannabis is microdosed primarily for medical reasons such as…
